Animal Health Solution - a Henry Schein Animal Health magazine for veterinary professionals
Issue link: https://www.e-digitaleditions.com/i/1503908
© 2023 Covetrus, Inc. All rights reserved. No copying without consent. Lit. No. 23CVB193 For complete product information, including safety, refer to the package insert. IMPORTANT SAFETY INFORMATION: INDICATIONS: Marbofloxacin Chewable Tablets are indicated for the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin. CONTRAINDICATIONS: Marbofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. Marbofloxacin is contraindicated in immature dogs during the rapid growth phase (small and medium breeds up to 8 months of age, large breeds up to 12 months of age and giant breeds up to 18 months of age). Marbofloxacin is contraindicated in cats under 12 months of age. Marbofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. WARNING: For use in animals only. Keep out of reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposure. Individuals with a history of hypersensitivity to fluoroquinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. Keep marbofloxacin in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. PRECAUTIONS: Quinolones should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolones have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. The safety of marbofloxacin in animals used for breeding purposes, pregnant, or lactating has not been demonstrated. ADVERSE REACTIONS: The following clinical signs were reported during the course of clinical field studies in dogs receiving marbofloxacin at dosages up to 2.5 mg/lb daily: decreased or loss of appetite (5.4%), decreased activity (4.4%), and vomiting (2.9%). The following signs were reported in less than 1% of cases in dogs: increased thirst, soft stool/diarrhea, behavioral changes, shivering/shaking/tremors, and ataxia. One dog which had a seizure the day before study enrollment experienced a seizure while on marbofloxacin therapy. The following clinical signs were reported during clinical field studies in cats receiving 1.25 mg/lb/day: diarrhea (2.1%) and soft stool (1.4%). Vomiting was reported in less than 1% of cases in cats. Order today at cvet.co/marbofloxacin 855.724.3461 | northamerica.covetrus.com For oral use in cats and dogs only A synthetic, broad-spectrum, antibacterial agent indicated for the treatment of skin and soft-tissue infections in cats and dogs and urinary tract infections in dogs Palatable soft chew Convenient once-a-day dosing Rapid and complete absorption from the gastrointestinal tract following oral administration to fasted animals CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.